JP2007501612A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007501612A5 JP2007501612A5 JP2006522535A JP2006522535A JP2007501612A5 JP 2007501612 A5 JP2007501612 A5 JP 2007501612A5 JP 2006522535 A JP2006522535 A JP 2006522535A JP 2006522535 A JP2006522535 A JP 2006522535A JP 2007501612 A5 JP2007501612 A5 JP 2007501612A5
- Authority
- JP
- Japan
- Prior art keywords
- nogo receptor
- antibody
- binding
- snogor310
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004965 antibodies Human genes 0.000 description 258
- 108090001123 antibodies Proteins 0.000 description 258
- 102000000343 Nogo Receptor 1 Human genes 0.000 description 241
- 108010041199 Nogo Receptor 1 Proteins 0.000 description 241
- 230000027455 binding Effects 0.000 description 163
- 210000004027 cells Anatomy 0.000 description 142
- 229920001184 polypeptide Polymers 0.000 description 125
- 241000700159 Rattus Species 0.000 description 107
- 239000000427 antigen Substances 0.000 description 70
- 102000038129 antigens Human genes 0.000 description 70
- 108091007172 antigens Proteins 0.000 description 70
- 210000000278 Spinal Cord Anatomy 0.000 description 67
- 230000014509 gene expression Effects 0.000 description 61
- 210000002569 neurons Anatomy 0.000 description 59
- 239000000835 fiber Substances 0.000 description 52
- 102000037240 fusion proteins Human genes 0.000 description 51
- 108020001507 fusion proteins Proteins 0.000 description 51
- 102000004169 proteins and genes Human genes 0.000 description 51
- 108090000623 proteins and genes Proteins 0.000 description 51
- 108020004707 nucleic acids Proteins 0.000 description 47
- 150000007523 nucleic acids Chemical class 0.000 description 47
- 235000018102 proteins Nutrition 0.000 description 47
- 210000002804 Pyramidal Tracts Anatomy 0.000 description 41
- 241000699660 Mus musculus Species 0.000 description 40
- 230000002401 inhibitory effect Effects 0.000 description 34
- 241000282414 Homo sapiens Species 0.000 description 33
- 206010022114 Injury Diseases 0.000 description 33
- 230000002163 immunogen Effects 0.000 description 32
- 102000005614 monoclonal antibodies Human genes 0.000 description 31
- 108010045030 monoclonal antibodies Proteins 0.000 description 31
- 230000000694 effects Effects 0.000 description 30
- 239000003446 ligand Substances 0.000 description 30
- 230000014511 neuron projection development Effects 0.000 description 30
- 230000003902 lesions Effects 0.000 description 29
- 239000000203 mixture Substances 0.000 description 28
- 210000000020 Growth Cones Anatomy 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- 238000000034 method Methods 0.000 description 21
- 210000003050 Axons Anatomy 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 20
- 230000003053 immunization Effects 0.000 description 18
- 238000002649 immunization Methods 0.000 description 17
- 210000003169 Central Nervous System Anatomy 0.000 description 16
- 239000003550 marker Substances 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 241000124008 Mammalia Species 0.000 description 15
- 102000005781 Nogo Receptors Human genes 0.000 description 15
- 108020003872 Nogo Receptors Proteins 0.000 description 15
- 210000004884 grey matter Anatomy 0.000 description 15
- 210000003594 Ganglia, Spinal Anatomy 0.000 description 14
- 102000018358 Immunoglobulins Human genes 0.000 description 14
- 108060003951 Immunoglobulins Proteins 0.000 description 14
- 125000000539 amino acid group Chemical group 0.000 description 14
- 238000002965 ELISA Methods 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 13
- 229920001850 Nucleic acid sequence Polymers 0.000 description 13
- 125000003275 alpha amino acid group Chemical group 0.000 description 13
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 13
- 230000001537 neural Effects 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 101700001678 ERCC2 Proteins 0.000 description 11
- 101700046384 MAG Proteins 0.000 description 11
- 102100008364 MAG Human genes 0.000 description 11
- 101710007617 MPG Proteins 0.000 description 11
- 210000002966 Serum Anatomy 0.000 description 11
- 208000008513 Spinal Cord Injury Diseases 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 11
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 11
- 230000001404 mediated Effects 0.000 description 11
- 229960000060 monoclonal antibodies Drugs 0.000 description 11
- 238000011084 recovery Methods 0.000 description 11
- 210000004885 white matter Anatomy 0.000 description 11
- 102000004851 Immunoglobulin G Human genes 0.000 description 10
- 210000003141 Lower Extremity Anatomy 0.000 description 10
- 101700014436 RTN4 Proteins 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 230000004927 fusion Effects 0.000 description 10
- 230000017308 neuron projection morphogenesis Effects 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 239000003981 vehicle Substances 0.000 description 10
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 9
- 101700069447 GFAP Proteins 0.000 description 9
- 210000004408 Hybridomas Anatomy 0.000 description 9
- 230000003042 antagnostic Effects 0.000 description 9
- 238000004166 bioassay Methods 0.000 description 9
- 108091006028 chimera Proteins 0.000 description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
- 230000001965 increased Effects 0.000 description 9
- 210000004901 leucine-rich repeat Anatomy 0.000 description 9
- 229920002866 paraformaldehyde Polymers 0.000 description 9
- 230000001105 regulatory Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 230000004083 survival Effects 0.000 description 9
- 239000000700 tracer Substances 0.000 description 9
- 210000002683 Foot Anatomy 0.000 description 8
- 210000000463 Red Nucleus Anatomy 0.000 description 8
- 230000003376 axonal Effects 0.000 description 8
- 230000002708 enhancing Effects 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 230000008929 regeneration Effects 0.000 description 8
- 238000011069 regeneration method Methods 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 241000283707 Capra Species 0.000 description 7
- 229920001405 Coding region Polymers 0.000 description 7
- 108010070144 Single-Chain Antibodies Proteins 0.000 description 7
- 102000005632 Single-Chain Antibodies Human genes 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 7
- 230000000240 adjuvant Effects 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 7
- 230000000890 antigenic Effects 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 125000005647 linker group Chemical group 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000003068 molecular probe Substances 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 230000001225 therapeutic Effects 0.000 description 7
- 210000001519 tissues Anatomy 0.000 description 7
- 230000001131 transforming Effects 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
- 101710027066 ALB Proteins 0.000 description 6
- ATDGTVJJHBUTRL-UHFFFAOYSA-N Cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 6
- 102100012570 GFAP Human genes 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 238000009227 behaviour therapy Methods 0.000 description 6
- 230000001809 detectable Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 229940079593 drugs Drugs 0.000 description 6
- 239000003623 enhancer Substances 0.000 description 6
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000001963 growth media Substances 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 230000003612 virological Effects 0.000 description 6
- 210000001130 Astrocytes Anatomy 0.000 description 5
- 229920002676 Complementary DNA Polymers 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102100018768 GPI Human genes 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- 239000007995 HEPES buffer Substances 0.000 description 5
- 229940092253 Ovalbumin Drugs 0.000 description 5
- 108010058846 Ovalbumin Proteins 0.000 description 5
- 230000003187 abdominal Effects 0.000 description 5
- 230000000202 analgesic Effects 0.000 description 5
- 230000003115 biocidal Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 230000000875 corresponding Effects 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000007913 intrathecal administration Methods 0.000 description 5
- 238000002684 laminectomy Methods 0.000 description 5
- 210000004962 mammalian cells Anatomy 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000002609 media Substances 0.000 description 5
- 230000001737 promoting Effects 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 238000003259 recombinant expression Methods 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 230000000862 serotonergic Effects 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 108010071919 Bispecific Antibodies Proteins 0.000 description 4
- 210000004556 Brain Anatomy 0.000 description 4
- 208000008313 Contusions Diseases 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 4
- 230000035693 Fab Effects 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 210000002241 Neurites Anatomy 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 101700044815 RTN4R Proteins 0.000 description 4
- 102100001715 RTN4RL1 Human genes 0.000 description 4
- 101710044032 RTN4RL1 Proteins 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 102000007312 Recombinant Proteins Human genes 0.000 description 4
- 108010033725 Recombinant Proteins Proteins 0.000 description 4
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000001580 bacterial Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000003636 conditioned culture media Substances 0.000 description 4
- 230000001054 cortical Effects 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- -1 fatty acid esters Chemical class 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000002823 phage display Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000001172 regenerating Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 230000002103 transcriptional Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 229940035676 ANALGESICS Drugs 0.000 description 3
- 210000001015 Abdomen Anatomy 0.000 description 3
- 210000000170 Cell Membrane Anatomy 0.000 description 3
- 241000699802 Cricetulus griseus Species 0.000 description 3
- 229940088598 Enzyme Drugs 0.000 description 3
- 210000003414 Extremities Anatomy 0.000 description 3
- 229960002743 Glutamine Drugs 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 230000036499 Half live Effects 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 3
- 210000003205 Muscles Anatomy 0.000 description 3
- 210000004897 N-terminal region Anatomy 0.000 description 3
- 102000000473 Nogo Receptor 2 Human genes 0.000 description 3
- 108010041253 Nogo Receptor 2 Proteins 0.000 description 3
- 210000004248 Oligodendroglia Anatomy 0.000 description 3
- 210000001672 Ovary Anatomy 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 210000003625 Skull Anatomy 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 210000003932 Urinary Bladder Anatomy 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000001413 cellular Effects 0.000 description 3
- 230000000295 complement Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229940042399 direct acting antivirals Protease inhibitors Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000003447 ipsilateral Effects 0.000 description 3
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 3
- 230000000670 limiting Effects 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000006011 modification reaction Methods 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 230000000324 neuroprotective Effects 0.000 description 3
- 230000003204 osmotic Effects 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 238000007747 plating Methods 0.000 description 3
- 229920000023 polynucleotide Polymers 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 238000001711 protein immunostaining Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 200000000019 wound Diseases 0.000 description 3
- BRZYSWJRSDMWLG-DJWUNRQOSA-N (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-[(1R)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 2
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 2
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-Diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 2
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 2
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 2
- 108010032595 Antibody Binding Sites Proteins 0.000 description 2
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 210000004899 C-terminal region Anatomy 0.000 description 2
- 101700060761 COS7 Proteins 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 210000000349 Chromosomes Anatomy 0.000 description 2
- 102000020504 Collagenase family Human genes 0.000 description 2
- 108060005980 Collagenase family Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 241000938605 Crocodylia Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N DEOXYTHYMIDINE Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 210000001951 Dura Mater Anatomy 0.000 description 2
- 229940110715 ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS Drugs 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 210000001723 Extracellular Space Anatomy 0.000 description 2
- 210000003194 Forelimb Anatomy 0.000 description 2
- 102000001389 Glial Fibrillary Acidic Protein Human genes 0.000 description 2
- 108010093505 Glial Fibrillary Acidic Protein Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 210000003284 Horns Anatomy 0.000 description 2
- 102000015434 Humanized Monoclonal Antibodies Human genes 0.000 description 2
- 108010064750 Humanized Monoclonal Antibodies Proteins 0.000 description 2
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 2
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 108020004999 Messenger RNA Proteins 0.000 description 2
- 210000000337 Motor Cortex Anatomy 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 210000003007 Myelin Sheath Anatomy 0.000 description 2
- 241000283898 Ovis Species 0.000 description 2
- 101700069774 PS14 Proteins 0.000 description 2
- 210000001428 Peripheral Nervous System Anatomy 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 239000012083 RIPA buffer Substances 0.000 description 2
- 102100003511 RTN4R Human genes 0.000 description 2
- 210000001609 Raphe Nuclei Anatomy 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 229940076279 Serotonin Drugs 0.000 description 2
- 210000003491 Skin Anatomy 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 210000000952 Spleen Anatomy 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002378 acidificating Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000002266 amputation Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 125000000511 arginine group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- 230000028600 axonogenesis Effects 0.000 description 2
- 230000003542 behavioural Effects 0.000 description 2
- 230000002146 bilateral Effects 0.000 description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000000903 blocking Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000002493 climbing Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000010192 crystallographic characterization Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000003247 decreasing Effects 0.000 description 2
- 108020001096 dihydrofolate reductase family Proteins 0.000 description 2
- 102000004419 dihydrofolate reductase family Human genes 0.000 description 2
- 239000002612 dispersion media Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 229940020899 hematological Enzymes Drugs 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000002055 immunohistochemical Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229940079866 intestinal antibiotics Drugs 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 229920002106 messenger RNA Polymers 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 230000000051 modifying Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 101710036448 neo Proteins 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 101700015794 pro Proteins 0.000 description 2
- 230000000750 progressive Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000002829 reduced Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 230000001429 stepping Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000002459 sustained Effects 0.000 description 2
- 230000000472 traumatic Effects 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 229960001322 trypsin Drugs 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 1
- RPAJSBKBKSSMLJ-DFWYDOINSA-N (2S)-2-aminopentanedioic acid;hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CCC(O)=O RPAJSBKBKSSMLJ-DFWYDOINSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- HMFKFHLTUCJZJO-HHVQYONYSA-N 2-[2-[(2R,3R)-3,4-bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-hydroxyethoxy)ethoxy]ethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOCC(OCCO)[C@H]1OCC(OCCO)[C@H]1OCCO HMFKFHLTUCJZJO-HHVQYONYSA-N 0.000 description 1
- OVXVQBCRONSPDC-UHFFFAOYSA-N 2-bromo-1,4-dichlorobenzene Chemical compound ClC1=CC=C(Cl)C(Br)=C1 OVXVQBCRONSPDC-UHFFFAOYSA-N 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N 2-mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-Bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 101710026914 AAG Proteins 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- 101710006647 APRT Proteins 0.000 description 1
- 102100007409 APRT Human genes 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229960000643 Adenine Drugs 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Natural products NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 206010001897 Alzheimer's disease Diseases 0.000 description 1
- 229960003896 Aminopterin Drugs 0.000 description 1
- 241000269328 Amphibia Species 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N Ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 210000003719 B-Lymphocytes Anatomy 0.000 description 1
- 229940064804 Betadine Drugs 0.000 description 1
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 1
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 1
- 102100006374 CASP1 Human genes 0.000 description 1
- 102100003814 CASP3 Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 210000002318 Cardia Anatomy 0.000 description 1
- 108090000426 Caspase 1 Proteins 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 210000003710 Cerebral Cortex Anatomy 0.000 description 1
- 206010008118 Cerebral infarction Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010070976 Craniocerebral injury Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N DATI Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 101710007887 DHFR Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 210000001787 Dendrites Anatomy 0.000 description 1
- 208000001636 Diabetic Neuropathy Diseases 0.000 description 1
- 206010012680 Diabetic neuropathy Diseases 0.000 description 1
- 102000004860 Dipeptidases Human genes 0.000 description 1
- 108090001081 Dipeptidases Proteins 0.000 description 1
- ZWIBGKZDAWNIFC-UHFFFAOYSA-N Disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 108010015776 EC 1.1.3.4 Proteins 0.000 description 1
- 210000001161 Embryo, Mammalian Anatomy 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N Ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229920000665 Exon Polymers 0.000 description 1
- 102220402096 FRAT2 L110A Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100011343 GLB1 Human genes 0.000 description 1
- 229940116332 GLUCOSE OXIDASE Drugs 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 201000001971 Huntington's disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229940102223 Injectable Solution Drugs 0.000 description 1
- 102000014429 Insulin-like growth factor Human genes 0.000 description 1
- 108050003490 Insulin-like growth factor Proteins 0.000 description 1
- 210000003093 Intracellular Space Anatomy 0.000 description 1
- 229920002459 Intron Polymers 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical group OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N L-serine Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 101700021338 LEC Proteins 0.000 description 1
- 101700048515 LEC1 Proteins 0.000 description 1
- 101700046135 LEC2 Proteins 0.000 description 1
- 101700077545 LECC Proteins 0.000 description 1
- 101700028499 LECG Proteins 0.000 description 1
- 101700028593 LECH Proteins 0.000 description 1
- 101700063913 LECT Proteins 0.000 description 1
- 229940067606 Lecithin Drugs 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 108060001084 Luciferase family Proteins 0.000 description 1
- 210000001165 Lymph Nodes Anatomy 0.000 description 1
- 210000004698 Lymphocytes Anatomy 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N Midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229960003793 Midazolam Drugs 0.000 description 1
- OLEKMOOQFWTQGD-SJQNMCRDSA-N NEP1-40 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(N)=O)C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1NC=NC=1)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(C)=O)[C@@H](C)CC)C(C)C)[C@@H](C)CC)[C@@H](C)CC)C1=CC=C(O)C=C1 OLEKMOOQFWTQGD-SJQNMCRDSA-N 0.000 description 1
- 108091007229 NSP3 Papain-like protease domain Proteins 0.000 description 1
- 241001045988 Neogene Species 0.000 description 1
- 210000004940 Nucleus Anatomy 0.000 description 1
- 101710034340 Os04g0173800 Proteins 0.000 description 1
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N PMSF Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 1
- 102200052297 POLD1 R119H Human genes 0.000 description 1
- 229940055729 Papain Drugs 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 206010061536 Parkinson's disease Diseases 0.000 description 1
- LPXQRXLUHJKZIE-UHFFFAOYSA-N Pathocidin Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004698 Polyethylene (PE) Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101000257793 RTN4RL2 Proteins 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N Rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 102200023749 SUFU D111A Human genes 0.000 description 1
- 210000004116 Schwann Cells Anatomy 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102100012087 TLR4 Human genes 0.000 description 1
- 229960002180 Tetracycline Drugs 0.000 description 1
- OFVLGDICTFRJMM-WESIUVDSSA-N Tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 229940104230 Thymidine Drugs 0.000 description 1
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 1
- 231100000765 Toxin Toxicity 0.000 description 1
- 208000005765 Traumatic Brain Injury Diseases 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- FPKOPBFLPLFWAD-UHFFFAOYSA-N Trinitrotoluene Chemical compound CC1=CC=C([N+]([O-])=O)C([N+]([O-])=O)=C1[N+]([O-])=O FPKOPBFLPLFWAD-UHFFFAOYSA-N 0.000 description 1
- 240000008529 Triticum aestivum Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 241000282485 Vulpes vulpes Species 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 101700041002 ant Proteins 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 230000000692 anti-sense Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003140 astrocytic Effects 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogens Species 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000001588 bifunctional Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000005081 chemiluminescent agent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000002759 chromosomal Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 230000001447 compensatory Effects 0.000 description 1
- 230000002860 competitive Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000023298 conjugation with cellular fusion Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- VOLSCWDWGMWXGO-UHFFFAOYSA-N cyclobuten-1-yl acetate Chemical compound CC(=O)OC1=CCC1 VOLSCWDWGMWXGO-UHFFFAOYSA-N 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000002354 daily Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000002939 deleterious Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 150000002019 disulfides Chemical group 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000010616 electrical installation Methods 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000002257 embryonic structures Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 230000001605 fetal Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 102000022218 human RTN4RL2 protein Human genes 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002318 immunoblotting Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000003308 immunostimulating Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001976 improved Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 101700036391 lecA Proteins 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 238000011068 load Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 101710026800 lyc Proteins 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000003867 nerve cell Anatomy 0.000 description 1
- 210000004255 neuroglia Anatomy 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002572 peristaltic Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) polymer Polymers 0.000 description 1
- 230000001402 polyadenylating Effects 0.000 description 1
- 108091008117 polyclonal antibodies Proteins 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000002980 postoperative Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 210000001938 protoplasts Anatomy 0.000 description 1
- 230000002285 radioactive Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000001177 retroviral Effects 0.000 description 1
- 108010083077 roundabout protein Proteins 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 230000003248 secreting Effects 0.000 description 1
- 230000001624 sedative Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000001954 sterilising Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000000576 supplementary Effects 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 230000000946 synaptic Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 102000002689 toll-like receptors Human genes 0.000 description 1
- 108020000411 toll-like receptors Proteins 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 235000002374 tyrosine Nutrition 0.000 description 1
- 125000001493 tyrosinyl group Chemical class [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000021037 unidirectional conjugation Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000021542 voluntary musculoskeletal movement Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003313 weakening Effects 0.000 description 1
- 230000003442 weekly Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000021307 wheat Nutrition 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2003/025004 WO2004014311A2 (en) | 2002-08-10 | 2003-08-07 | Nogo receptor antagonists |
| PCT/US2004/002702 WO2005016955A2 (en) | 2003-08-07 | 2004-01-30 | Nogo receptor antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010106824A Division JP2010207239A (ja) | 2002-08-10 | 2010-05-06 | Ｎｏｇｏ受容体アンタゴニスト |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007501612A JP2007501612A (ja) | 2007-02-01 |
| JP2007501612A5 true JP2007501612A5 (ko) | 2007-03-15 |
Family
ID=34192565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006522535A Pending JP2007501612A (ja) | 2003-08-07 | 2004-01-30 | Ｎｏｇｏ受容体アンタゴニスト |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1660517A4 (ko) |
| JP (1) | JP2007501612A (ko) |
| CN (1) | CN1926147A (ko) |
| AU (1) | AU2004264405A1 (ko) |
| BR (1) | BRPI0413426A (ko) |
| CA (1) | CA2535007A1 (ko) |
| IS (1) | IS8339A (ko) |
| MX (1) | MXPA06001444A (ko) |
| NO (1) | NO20061081L (ko) |
| PL (1) | PL380274A1 (ko) |
| WO (1) | WO2005016955A2 (ko) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7119165B2 (en) | 2000-01-12 | 2006-10-10 | Yale University | Nogo receptor-mediated blockade of axonal growth |
| DK1534736T3 (da) | 2002-08-10 | 2010-09-20 | Biogen Idec Inc | Nogo-receptorantagonister |
| ES2215470B1 (es) | 2002-09-30 | 2005-12-16 | Bsh Electrodomesticos España, S.A. | Aparato de aire acondicionado. |
| ES2215469B1 (es) | 2002-09-30 | 2005-12-16 | Bsh Electrodomesticos España, S.A. | Aparato de aire acondicionado. |
| EP1606409B1 (en) | 2003-03-19 | 2010-09-01 | Biogen Idec MA Inc. | Nogo receptor binding protein |
| RS52593B (en) | 2004-06-24 | 2013-04-30 | Biogen Idec Ma Inc. | TREATMENT OF THE CONDITIONS CONCERNING DEMYELINIZATION |
| CN101014245A (zh) | 2004-08-03 | 2007-08-08 | 比奥根艾迪克Ma公司 | 神经元功能中的taj |
| WO2006124627A2 (en) * | 2005-05-12 | 2006-11-23 | Biogen Idec Ma Inc. | Methods of treating conditions involving neuronal degeneration |
| WO2007008732A2 (en) | 2005-07-07 | 2007-01-18 | Yale University | Compositions and methods for suppressing axonal growth inhibition |
| SG10201508322SA (en) | 2005-07-08 | 2015-11-27 | Biogen Ma Inc | Sp35 antibodies and uses thereof |
| ES2542501T3 (es) | 2005-09-30 | 2015-08-06 | Abbvie Deutschland Gmbh & Co Kg | Dominios de unión de proteínas de la familia de proteínas de moléculas de orientación repulsiva (RGM) y fragmentos funcionales de las mismas, así como su uso |
| PT1981902E (pt) | 2006-01-27 | 2015-11-02 | Biogen Ma Inc | Antagonistas dos recetores nogo |
| WO2008013782A2 (en) | 2006-07-24 | 2008-01-31 | Biogen Idec Ma Inc. | Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of sp35 or trka antagonists |
| EP2081562B1 (en) | 2006-09-20 | 2016-02-24 | The Board of Regents of The University of Texas System | Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief |
| CA2987970A1 (en) * | 2006-11-21 | 2008-05-29 | Abbvie Inc. | Neutralizing monoclonal antibodies against the nogo-66 receptor (ngr) and uses thereof |
| CN107661293A (zh) | 2008-01-22 | 2018-02-06 | 得克萨斯大学体系董事会 | 用于局部麻醉和/或疼痛缓解的含有萃取溶剂的挥发性麻醉剂组合物 |
| US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
| EP2315779A2 (en) | 2008-07-09 | 2011-05-04 | Biogen Idec MA Inc. | Compositions comprising antibodies to lingo or fragments thereof |
| BR112012013734A2 (pt) | 2009-12-08 | 2017-01-10 | Abbott Gmbh & Co Kg | anticorpos monoclonais contra a proteína rgm a para uso no tratamento da degeneração da camada de fibras nervosas da retina. |
| CN104487455A (zh) | 2012-01-27 | 2015-04-01 | 艾伯维德国有限责任两合公司 | 用于诊断和治疗与神经突变性相关的疾病的组合物和方法 |
| WO2013173364A2 (en) | 2012-05-14 | 2013-11-21 | Biogen Idec Ma Inc. | Lingo-2 antagonists for treatment of conditions involving motor neurons |
| WO2016112270A1 (en) | 2015-01-08 | 2016-07-14 | Biogen Ma Inc. | Lingo-1 antagonists and uses for treatment of demyelinating disorders |
| CN110488007A (zh) * | 2019-09-26 | 2019-11-22 | 天津华科泰生物技术有限公司 | 一种快速检测神经胶质纤维酸性蛋白的免疫层析检测卡及其制备方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2331154A1 (en) * | 1998-06-16 | 1999-12-23 | Human Genome Sciences, Inc. | Polypeptides having sequence identity with acid labile subunit of insulin-like growth factor |
| US20050221420A1 (en) * | 2001-10-22 | 2005-10-06 | Carmen Barske | Nogo receptor homologues and their use |
-
2004
- 2004-01-30 PL PL380274A patent/PL380274A1/pl not_active Application Discontinuation
- 2004-01-30 WO PCT/US2004/002702 patent/WO2005016955A2/en active Application Filing
- 2004-01-30 CA CA002535007A patent/CA2535007A1/en not_active Abandoned
- 2004-01-30 BR BRPI0413426-5A patent/BRPI0413426A/pt not_active IP Right Cessation
- 2004-01-30 CN CNA2004800294122A patent/CN1926147A/zh active Pending
- 2004-01-30 AU AU2004264405A patent/AU2004264405A1/en not_active Abandoned
- 2004-01-30 EP EP04707073A patent/EP1660517A4/en not_active Withdrawn
- 2004-01-30 MX MXPA06001444A patent/MXPA06001444A/es unknown
- 2004-01-30 JP JP2006522535A patent/JP2007501612A/ja active Pending
-
2006
- 2006-03-06 NO NO20061081A patent/NO20061081L/no not_active Application Discontinuation
- 2006-03-07 IS IS8339A patent/IS8339A/is unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010207239A (ja) | Ｎｏｇｏ受容体アンタゴニスト | |
| JP2007501612A5 (ko) | ||
| JP2007501612A (ja) | Ｎｏｇｏ受容体アンタゴニスト | |
| JP5829373B2 (ja) | Ｎｏｇｏレセプターアンタゴニスト | |
| EP2732823B1 (en) | Modulation of the TrpV : Vps10p-domain receptor system for the treatment of pain | |
| US7691590B2 (en) | Reducing myelin-mediated inhibition of axon regeneration | |
| EP1928905B1 (de) | Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung | |
| US20070031418A1 (en) | Methods for treating lower motor neuron diseases and compositions containing the same | |
| US20150239973A1 (en) | Modulation of the Interaction Between SorLA and GDNF-Family Ligand Receptors | |
| US20080274112A1 (en) | Nogo Receptor Antagonists | |
| TW200950808A (en) | Anti-PirB antibodies | |
| KR19990007893A (ko) | 중추신경계（ｃｎｓ） 축삭 성장 모듈레이터, 이를 구현 및 사용하는 조성물, 세포 및 방법 | |
| KR20070052237A (ko) | 노고 수용체 길항제를 사용한, 도파민성 신경 퇴행을수반하는 상태의 치료법 | |
| EP1534736B1 (en) | Nogo receptor antagonists | |
| KR20060072122A (ko) | Ｎｏｇｏ 수용체 길항제 |